Literature DB >> 2884254

The interaction of the xid and me genes.

C L Scribner, C T Hansen, D M Klinman, A D Steinberg.   

Abstract

The murine "motheaten" (me) mutation has been bred onto the NFS background and combined with the X-linked immunodeficiency (xid) mutation to investigate the effect of the xid-induced B cell maturational block on the widespread immune dysfunction, high levels of autoantibodies, and early mortality found in the motheaten mice. The xid markedly reduced spontaneous IgM secretion by spleen cells, serum IgM, anti-ssDNA antibodies, anti-bromelain-treated-erythrocyte antibodies, and T cell binding (but not thymocytotoxic) antibodies; however, neither phenotype nor mortality was affected, suggesting that other factors are responsible for early death. Marked expansion of the Ly-1+ B cell pool was prevented by xid in the motheaten mouse leaving only a very small population of sIgM-positive B cells. This failure of non-Ly-1+ B cell development in me/me X xid mice suggests that me/me leads to inhibition of non-Ly-1+ B cells and preferential expansion of Ly-1+ B cells in motheaten mice, perhaps as a result of their high levels of maturation and activation factors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884254

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.

Authors:  Wei Kong; Wei Deng; Yue Sun; Saisai Huang; Zhuoya Zhang; Bingyu Shi; Weiwei Chen; Xiaojun Tang; Genhong Yao; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

Review 2.  Shp1 function in myeloid cells.

Authors:  Clare L Abram; Clifford A Lowell
Journal:  J Leukoc Biol       Date:  2017-06-12       Impact factor: 4.962

3.  Btk dosage determines sensitivity to B cell antigen receptor cross-linking.

Authors:  A B Satterthwaite; H Cheroutre; W N Khan; P Sideras; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Adoptive transfer of viable motheaten pathology in sublethally irradiated beige recipient mice.

Authors:  L Kuntz; E Montecino-Rodriguez; B Jachez; D Roman; F Loor
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

5.  Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses.

Authors:  Andrew B Nesterovitch; Zsuzsa Gyorfy; Mark D Hoffman; Ellen C Moore; Nada Elbuluk; Beata Tryniszewska; Tibor A Rauch; Melinda Simon; Sewon Kang; Gary J Fisher; Katalin Mikecz; Michael D Tharp; Tibor T Glant
Journal:  Am J Pathol       Date:  2011-03-04       Impact factor: 4.307

6.  Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells.

Authors:  Kristina E Halcomb; Sandirai Musuka; Toni Gutierrez; Heather L Wright; Anne B Satterthwaite
Journal:  Mol Immunol       Date:  2008-10-11       Impact factor: 4.407

7.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Authors:  Betty Y Chang; Min Mei Huang; Michelle Francesco; Jun Chen; Jeremy Sokolove; Padmaja Magadala; William H Robinson; Joseph J Buggy
Journal:  Arthritis Res Ther       Date:  2011-07-13       Impact factor: 5.156

8.  Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways.

Authors:  A B Satterthwaite; C A Lowell; W N Khan; P Sideras; F W Alt; O N Witte
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

9.  B and T cells are not required for the viable motheaten phenotype.

Authors:  C C Yu; H W Tsui; B Y Ngan; M J Shulman; G E Wu; F W Tsui
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

10.  The motheaten mutation rescues B cell signaling and development in CD45-deficient mice.

Authors:  G Pani; K A Siminovitch; C J Paige
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.